Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Breast Cancer, Ovarian Cancer, and Glioblastoma Clinical Trials

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7
Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): Final results of a randomized, multi-center, phase III trial
Roger Stupp
University Hospital Zurich & Northwestern University, Zurich & Chicago, Switzerland
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
Panagiotis A Konstantinopoulos
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study
Joyce F Liu
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Efficacy results based on PIK3CA status in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor
Ruth O'Regan
University of Wisconsin Carbone Cancer Center, Madison, WI, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)
Cynthia Ma
Washington University School of Medicine, St. Louis, MO, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
Novel effect of tamoxifen therapy: disruption of ER-p53 interaction leading to altered gene expression profile in human breast tumors
Gokul M. Das
Roswell Park Cancer Inst., Buffalo, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC)
Jame Abraham
NSABP, and The Cleveland Clinic, Cleveland, OH, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7